We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rituximab for recurrent IgA nephropathy in kidney transplantation: A report of three cases and proposed mechanisms.
- Authors
Chancharoenthana, Wiwat; Townamchai, Natavudh; Leelahavanichkul, Asada; Wattanatorn, Salin; Kanjanabuch, Talerngsak; Avihingsanon, Yingyos; Praditpornsilpa, Kearkiat; Eiam‐Ong, Somchai
- Abstract
Aim Recurrent IgA nephropathy (IgAN) is a common recurrent glomerular disease after kidney transplantation. Recurrent IgAN, in particular, with crescent formation or endocapillary proliferation might result in kidney allograft loss. However, the current treatment options of recurrent IgAN are conflicting. Methods We have reported three kidney-transplanted recipients with biopsy-proven recurrent IgAN treated with four consecutive months of rituximab at the dose of 375 mg/1.73m2 without corticosteroids. Results At median follow-up 20 months following rituximab administration, all three recipients demonstrated decrease in proteinuria severity, slow disease progression with a well-tolerated condition. This therapeutic effect is most probably mediated by the B cell depletion. Conclusion Our three case reports suggest that the disease severity of recurrent IgAN with endocapillary proliferation regardless of crescent formation can be minimized by the four doses of monthly rituximab regimen.
- Subjects
RITUXIMAB; IGA glomerulonephritis; KIDNEY transplantation; PROTEINURIA treatment; B cells; PATIENTS
- Publication
Nephrology, 2017, Vol 22, Issue 1, p65
- ISSN
1320-5358
- Publication type
Article
- DOI
10.1111/nep.12722